Bevacizumab-Related Osteneocrosis of the Jaw
Bevacizumab-Related Osteneocrosis of the Jaw
复制标题
贝伐珠单抗相关的颌骨坏死
DOI：
10.1177/039463200902200429
复制
发表时间：
2009
影响因子：
3.5
通讯作者：
M. Dolci
中科院分区：
文献类型：
--
作者：
E. Serra;M. Paolantonio;Giuseppe Spoto;Filiberto Mastrangelo;Stefano Tetè;M. Dolci
We describe a case of jaw bone necrosis after a lung adenocarcinoma bone metastasis, treated the first time in 2004 by means of pneumonectomy and lymph node ablation. One week after a dental extraction, the patient experienced pain in the mandibular region, in conjunction with alveolar bone exposure. Treatment with amoxicillin and clavulanate every 12 hours for 15 days and 0.2% chlorhexidine rinses was administered and there was a remission of infective complications, but not the closure of the exposed alveolar bone. Only at this time did the patient refer that he was treated with bevacizumab therapy immediately after the extraction. A preventive dental assessment of patients scheduled for bevacizumab therapy should be useful as for the zoledronic acid therapy. Dental surgery procedures for patients during bevacizumab therapy should be carefully evaluated and considered as the last choice, to reduce all possible risks and prevent complications.
